NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion

Abstract Dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD) is a carcinogenic and highly toxic industrial byproduct that persists in the environment and produces a pleiotropic toxicity syndrome across vertebrate species that includes wasting, hepatosteatosis, and thymus atrophy. Dioxin toxicities re...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Silvia Diani-Moore, Jenny Shoots, Rubi Singh, Joshua B. Zuk, Arleen B. Rifkind
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
R
Q
Acceso en línea:https://doaj.org/article/2ec744b98cec42aba26d391463ce2a99
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:2ec744b98cec42aba26d391463ce2a99
record_format dspace
spelling oai:doaj.org-article:2ec744b98cec42aba26d391463ce2a992021-12-02T12:30:12ZNAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion10.1038/s41598-017-02332-92045-2322https://doaj.org/article/2ec744b98cec42aba26d391463ce2a992017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02332-9https://doaj.org/toc/2045-2322Abstract Dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD) is a carcinogenic and highly toxic industrial byproduct that persists in the environment and produces a pleiotropic toxicity syndrome across vertebrate species that includes wasting, hepatosteatosis, and thymus atrophy. Dioxin toxicities require binding and activation of the aryl hydrocarbon receptor (AhR), a ligand activated transcription factor. However, after nearly 50 years of study, it remains unknown how AhR activation by dioxin produces toxic effects. Here, using the chick embryo close to hatching, a well-accepted model for dioxin toxicity, we identify NAD+ loss through PARP activation as a novel unifying mechanism for diverse effects of dioxin in vivo. We show that NAD+ loss is attributable to increased PARP activity in thymus and liver, as cotreatment with dioxin and the PARP inhibitor PJ34 increased NAD+ levels and prevented both thymus atrophy and hepatosteatosis. Our findings additionally support a role for decreased NAD+ dependent Sirt6 activity in mediating dioxin toxicity following PARP activation. Strikingly, treatment in vivo with the NAD+ repleting agent nicotinamide, a form of vitamin B3, prevented thymus atrophy and hepatosteatosis by dioxin and increased sirtuin activity, providing a therapeutic approach for preventing dioxin toxicities in vivo.Silvia Diani-MooreJenny ShootsRubi SinghJoshua B. ZukArleen B. RifkindNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Silvia Diani-Moore
Jenny Shoots
Rubi Singh
Joshua B. Zuk
Arleen B. Rifkind
NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion
description Abstract Dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD) is a carcinogenic and highly toxic industrial byproduct that persists in the environment and produces a pleiotropic toxicity syndrome across vertebrate species that includes wasting, hepatosteatosis, and thymus atrophy. Dioxin toxicities require binding and activation of the aryl hydrocarbon receptor (AhR), a ligand activated transcription factor. However, after nearly 50 years of study, it remains unknown how AhR activation by dioxin produces toxic effects. Here, using the chick embryo close to hatching, a well-accepted model for dioxin toxicity, we identify NAD+ loss through PARP activation as a novel unifying mechanism for diverse effects of dioxin in vivo. We show that NAD+ loss is attributable to increased PARP activity in thymus and liver, as cotreatment with dioxin and the PARP inhibitor PJ34 increased NAD+ levels and prevented both thymus atrophy and hepatosteatosis. Our findings additionally support a role for decreased NAD+ dependent Sirt6 activity in mediating dioxin toxicity following PARP activation. Strikingly, treatment in vivo with the NAD+ repleting agent nicotinamide, a form of vitamin B3, prevented thymus atrophy and hepatosteatosis by dioxin and increased sirtuin activity, providing a therapeutic approach for preventing dioxin toxicities in vivo.
format article
author Silvia Diani-Moore
Jenny Shoots
Rubi Singh
Joshua B. Zuk
Arleen B. Rifkind
author_facet Silvia Diani-Moore
Jenny Shoots
Rubi Singh
Joshua B. Zuk
Arleen B. Rifkind
author_sort Silvia Diani-Moore
title NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion
title_short NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion
title_full NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion
title_fullStr NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion
title_full_unstemmed NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion
title_sort nad+ loss, a new player in ahr biology: prevention of thymus atrophy and hepatosteatosis by nad+ repletion
publisher Nature Portfolio
publishDate 2017
url https://doaj.org/article/2ec744b98cec42aba26d391463ce2a99
work_keys_str_mv AT silviadianimoore nadlossanewplayerinahrbiologypreventionofthymusatrophyandhepatosteatosisbynadrepletion
AT jennyshoots nadlossanewplayerinahrbiologypreventionofthymusatrophyandhepatosteatosisbynadrepletion
AT rubisingh nadlossanewplayerinahrbiologypreventionofthymusatrophyandhepatosteatosisbynadrepletion
AT joshuabzuk nadlossanewplayerinahrbiologypreventionofthymusatrophyandhepatosteatosisbynadrepletion
AT arleenbrifkind nadlossanewplayerinahrbiologypreventionofthymusatrophyandhepatosteatosisbynadrepletion
_version_ 1718394388828127232